Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2018 08:30 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018

SAN DIEGO, March 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, announced that it has released financial results for the full...
March 12, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive

Advancing 6- and 12- month injectable contraceptive development work carried out to date under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda...
March 05, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference

SAN DIEGO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson,...
February 27, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and...
February 15, 2018 11:06 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder

SAN DIEGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement for...
February 13, 2018 09:18 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to raise approximately $10.25 million

SAN DIEGO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its...
February 12, 2018 20:57 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock

SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its...
February 12, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder

Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré...
February 06, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference

SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s...
December 04, 2017 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right